Venetoclax Based Regimen for R/R T-ALL
This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.
Acute T-Lymphocytic Leukemia
DRUG: Venetoclax combined with azacitidine regimen
Overall Response Rate (ORR), The overall response (complete remission, complete remission with incomplete blood count recovery) rate achieved after one or two courses (21 days) induction therapy by venetoclax combined azacitidine regimen., At the end of Cycle 1 (each cycle is 21 days)|Complete Remission Rate (CRR), The complete remission rate achieved after one or two courses (21 days) induction therapy by venetoclax combined azacitidine regimen., At the end of Cycle 1 (each cycle is 21 days)
Overall survial (OS), It is measured from the date of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive., 1 year|Relapse-Free Survival (RFS), It is measured from the date of entry into this trial to the date of hematologic relapse or death from any cause., 1 year|Adverse events in hematological system, Record of adverse events in hematological system during and after designed venetoclax combined azacitidine regimen induction., 1 month|Adverse events in other organs or systems, Record of adverse events in other organs or systmes during and after designed venetoclax combined azacitidine regimen induction., 1 month
This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.